PureGen Osteoprogenitor Cell Allograft

PreclinicalBiologic

AAlphatec Spine, Inc.

PureGen Osteoprogenitor Cell Allograft is one of 7 biologic programs targeting Bone. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BoneTerminated

BonePreclinical

Terminated

Competition

Competitive Landscape

11 competitors in Bone

#DrugCompanyPhaseTrials

Invanz

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 2

BOOST Cells

KKarolinska Institutet

Phase 2

1 3

Bone Marrow Aspirate Concentrate

MMassachusetts General Hospital

Preclinical

2 4

Platelet-Rich Fibrin (PRF)

FFederal University of São Paulo

Preclinical

1 5

Vertebral Bone Marrow Clot

IIstituto Ortopedico Rizzoli

Preclinical

1 6

PureGen Osteoprogenitor Cell Allograft

AAlphatec Spine, Inc.

Preclinical

1 7

Elelyso

SShaare Zedek Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone1 trial

Radiographic Analysis Using PureGen Versus Autologous Bone in Posterolateral Fusion (PLF)

Terminated·AAlphatec Spine, Inc.·N/A·NCT01294007·1 enrolled

Outcome1 trial

Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)

Terminated·AAlphatec Spine, Inc.··NCT01293981·6 enrolled

Unspecified1 trial

PureGen: Radiographic Analysis of Fusion for ACDF

Terminated·AAlphatec Spine, Inc.··NCT01291134·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PureGen Osteoprogenitor Cell Allograft. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PureGen Osteoprogenitor Cell Allograft compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PureGen Osteoprogenitor Cell Allograft. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alphatec Spine, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAlphatec Spine, Inc.

PureGen Osteoprogenitor Cell Allograft

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone1 trial

Outcome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News